Mass spectrometry techniques in the survey of steroid metabolites as potential disease biomarkers: A review by Maria Joao Gouveia et al.
M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 2 ( 2 0 1 3 ) 1 2 0 6 – 1 2 1 7
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
Metabolism
www.metabo l i sm jou rna l . comMass spectrometry techniques in the survey of steroid
metabolites as potential disease biomarkers: A reviewMaria João Gouveiaa, b, Paul J. Brindley c, Lúcio Lara Santosd,
José Manuel Correia da Costaa, b, Paula Gomese, Nuno Vale e,⁎
a Center for the Study of Animal Science, ICETA, University of Porto
b INSA, Rua Alexandre Herculano, 321, 4000-055 Porto, Portugal
c George Washington University School of Medicine & Health Sciences-Department of Microbiology, Immunology and Tropical Medicine,
Ross Hall, 20037, Washington, DC, USA
d Experimental Therapeutics and Pathology Research Group-IPO-Porto, Portuguese Institute of Oncology Francisco Gentil, Rua Dr António
Bernardino de Almeida, 4200-072 Porto, Portugal
e CIQUP, Chemistry and Biochemistry Department, Faculty of Sciences, University of Porto, Rua Campo Alegre, 687, 4169-007 Porto, PortugalA R T I C L E I N F OAbbreviations: APCI–MS, Atmospheric-pre
izationmass spectrometry; CA, Cholic acid; C
Collision-induced dissociation; COMT, Catech
injection analysis; FTMS, Fourier transform
EDC, High performance liquid chromatograph
TOF, Matrix-assisted laser desorption/ioniz
acetyldopamine-quinone; NQO-2, NRH quino
syndrome; SRM, Selected reaction monitori
mass spectrometry.
⁎ Corresponding author. CIQUP, Chemistry an
687, P-4169-007 Porto, Portugal. Tel.: +351 22
E-mail address: nuno.vale@fc.up.pt (N. Va
0026-0495/$ – see front matter. Crown Copyr
http://dx.doi.org/10.1016/j.metabol.2013.04.00A B S T R A C TArticle history:
Received 18 December 2012
Accepted 2 April 2013Mass spectrometric approaches have been fundamental to the identification of metabolites
associated with steroid hormones, yet this topic has not been reviewed in depth in recent
years. To this end, and given the increasing relevance of liquid chromatography–mass
spectrometry (LC–MS) studies on steroid hormones and their metabolites, the present
review addresses this subject. This review provides a timely summary of the use of various
mass spectrometry-based analytical techniques during the evaluation of steroidal
biomarkers in a range of human disease settings. The sensitivity and specificity of these
technologies are clearly providing valuable new insights into breast cancer and
cardiovascular disease.
We aim to contribute to an enhanced understanding of steroid metabolism and how it can
be profiled by LC–MS techniques.
Crown Copyright © 2013 Published by Elsevier Inc. All rights reserved.Keywords:
Mass spectrometry
LC–MS
Estradiol metabolites
Cholesterol metabolites
Cancer biomarkers1. Mass spectrometry overview
Mass spectrometry has an important history in the identifi-
cation of drug metabolites and has recently emerged as thessure chemical ionization
AT, 1,2-Dihydroxybenzen
ol-O-methyltransferase;
mass spectrometry; GC–M
y–electro-chemical detec
ation-time-of-flight; N-A
ne oxidoreductase 2; Resv
ng; TOF, Time-of-flight; U
d Biochemistry Departme
0402567; fax: + 351 220402
le).
ight © 2013 Published by
3foremost technology in endogenous metabolite research [1],
given its proven success in drug metabolite analysis and
pharmacokinetic studies [2–12]. In fact, the recent rise of the
«metabolomics era» stems from the enhanced ability tomass spectrometry; APPI–MS, Atmospheric-pressure photoion-
e (benzene catechol); CAT-Q, 1,2-Dihydroxybenzene-Quinone; CID,
DCA, Deoxycholic acid; ESI–MS, Electrospray ionization; FIA, Flow
S, Gas chromatography–mass spectrometry; GP, Girard P; HPLC–
tion; LC–MS, Liquid chromatography–mass spectrometry; MALDI-
cCys, N-acetylcysteine; NADA, N-acetyldopamine; NADA-Q, N-
, Resveratrol; SPE, Solid phase extration; SLOS, Smith–Lemli–Opitz
PLC–MS/MS, Ultra-performance liquid chromatography-tandem
nt, Faculty of Sciences, University of Porto, Rua do Campo Alegre,
563.
Elsevier Inc. All rights reserved.
1207M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 2 ( 2 0 1 3 ) 1 2 0 6 – 1 2 1 7perform faster, more accurate and comprehensive metabolite
analyses, along with the need to understand intracellular
biochemical events towards identification of both disease and
pharmaceutical biomarkers [1].
Metabolite analyses have been typically carried out by
means of liquid or gas chromatography with mass spectrom-
etry (LC–MS or GC–MS, respectively), or inclusively high field
proton nuclear magnetic resonance (NMR). The primary
advantage of NMR in metabolite analysis is its ability to
measure analytes in biofluids quickly and accurately, without
the need of initial processing or separation [13–15]. Over
recent years, improvements have included higher spectral
resolution, lower instrument cost, and the addition of stop-
flow chromatography on fractions of samples. Yet, the major
weakness of NMR is that it has a poor dynamic range (100–
1000) that results in only the major components being
observed [1]. High-resolution capillary GC–MS has also been
a landmark inmetabolite research and disease diagnosis, as it
enables identification of key small molecules, such as fatty
acids, amino acids and organic acids, in biofluids, particularly
in urine and blood [16–18]. This technique has been influential
in providing diagnostic information for many inherited
diseases, such as numerous metabolic disorders, disorders
of themetabolism of amino acids [19–22], bile acids [23,24] and
steroids [25–27]. Nevertheless, GC–MS techniques have limited
applicability to metabolite profiling, as they usually require (i)
convoluted sample preparation including metabolite extrac-
tion and subsequent derivatization to volatile adducts, (ii) long
analysis times, and (iii) ideal size and type of molecules to be
analyzable; in other words, non-volatile, highly polar and/or
large molecules cannot be studied by GC–MS [1]. In this
context, LC–MS techniques present several advantages over
NMR or GC–MS techniques in metabolite profiling, namely
greater sensitivity and dynamic range. Therefore, LC–MS
techniques will be overviewed in greater detail.2. Competing MS technologies
LC–MS with an electrospray ionization interface (LC–ESI–MS)
has become a popular choice for metabolite analysis and
studies for new biomarkers [18,28]. This technique is advan-
tageous over GC–MS in that sample preparation and analysis
are relatively simple, providing access tometabolites of higher
structural diversity. ESI offers many advantages over other
ionization techniques, for example, the ability to analyze low-
and high-molecular weight compounds, excellent quantita-
tive capabilities and reproducibility, high sensitivity, simple
sample preparation, amenability to automation, soft ioniza-
tion and absence of matrix [29]. The utility of ESI lies in its
ability to generate gas-phase ions directly from the liquid
phase, which establishes the technique as a convenientmass-
analysis platform for both LC and direct flow injection
analysis (FIA), especially when combined with tandem mass
spectrometry (MS/MS) [1]. While previous LC separation of the
diverse molecules present in biofluids can reduce ESI ion
suppression [30–32], making LC–MS especially attractive in the
initial stages of metabolite research, it also delays data
acquisition and analysis. Therefore, for ESI–MS quantitation
of a known biomarker, extraction combined with flowinjection analysis (FIA) is the method of choice, as the
extracted sample is directly injected into the mass spectrom-
eter, without prior chromatographic separation [33]. Altogeth-
er, ESI–MS techniques result in a selective approach that
allows for both qualitative and quantitative metabolite
analysis, while sensitivities in the pg/mL range can be readily
achieved [34]. Still, a challenge in metabolite profiling is that
potential biomarkers may be present in the biofluid in even
lower abundances, thus requiring especially sensitive tech-
niques, like nano-LC–ESI–MS; this technique is performed at
flow rates (~200 nL · min−1) much lower than those in
standard LC–ESI–MS (~300 μL · min−1), which produces ions
with less evaporation, thus enabling detection of highly
diluted species. This improves the sensitivity and ultimately
offers a greater dynamic range inmetabolite discovery [30–36].
Finally, though atmospheric-pressure chemical or photo-
ionization mass spectrometry (APCI–MS or APPI–MS, respec-
tively) is not widely used inmetabolite-profiling studies, these
techniques have been employed in the analysis of more easily
ionizable molecules, such as phospholipids, to produce
molecular and fragment ions complementary to those
obtained by ESI with collision-induced dissociation (CID).
APCI–MS provides a dynamic range higher than ESI–MS and
is considered robust, easy to operate and relatively tolerant to
higher buffer concentrations. Yet, it is a mass-sensitive rather
than concentration-sensitive technique, so no sensitivity gain
can be reached with smaller columns or lower flow rates.
A summary of the main characteristics of the techniques
outlined above is provided in Table 1.
Another critical parameter in MS-based metabolite studies
is themass analyzer, a central piece in the performance of any
mass spectrometer. Among the most commonly used are the
quadrupole, the quadrupole ion trap, the time-of-flight (TOF)
reflectron, and the Fourier transform ion cyclotron resonance
(FTMS) analyzer.
Quadrupole is presently the most common type of mass
analyzers; quadrupoles tolerate relatively high pressures,
have the capability of analyzing up to an m/z of 4000 and
are relatively low cost instruments. Yet, a triple-quadrupole is
required if tandemmass analysis is to be performed; the three
quadrupoles are placed in series, and each of them has a
separate function: the first (Q1) is used to scan across the full
m/z range and select an ion of interest; the second (Q2), also
known as the collision cell, focuses and transmits the ions
while introducing a collision gas (argon or helium) into the
flight path of the selected ion; the third (Q3) serves to analyze
the fragment ions generated in the collision cell (Q2) [29].
Quadrupole ion trap analyzers are also useful in tandem
MS analysis, as a single ion species can be isolated by ejecting
all others from the trap, enabling the isolated species to be
further fragmented by collisional activation (CID); a key
advantage of quadrupole ion traps is that multiple CID
experiments can be performed quickly without requiring
multiple analyzers. Other advantages include their ability to
trap and accumulate ions to provide a better signal-to-noise
ratio and their mass range up to ~4000 m/z. Yet, quadrupole
ion traps are unable to perform high-sensitivity triple
quadrupole-type precursor-ion scanning and neutral loss
scanning experiments. Also, the upper limit on the ratio
between precursorm/z and the lowest trapped fragment ion is
Table 1 – Summaryof themajorcharacteristicsofLC–MS,FIA,GC–MSandNMRtechniquesused inmetabolite-profilingstudies.
Technique
Characteristics
LC–MS FIA GC–MS NMR
Sample preparation extraction extraction Extraction and chemical
modification
Typically none
Chromatographic
Separation
Medium-resolution
separation
No separation High-resolution separation No separation
Sensitivity Millimoles per liter
to nanomoles per liter
Millimoles per liter to
micromoles per liter
Millimoles per liter to
nanomoles per liter
Millimoles per liter to high
micromoles per liter
Dynamic range 106 104 106 103
Speed Slow (5–90 min) Rapid (1 to 5 min) Slow (~30 min) Rapid (1 to 5 min)
Quantitative
accuracy
±10% ±10% ±10% ±10%
Significant
advantages
Soft ionization
Large mass range
Data in one spectrum fast High resolution ESI–MS library
available
No sample preparation
Significant
disadvantages
Speed of analysis Signal suppression from
multiple components
Significant sample preparation
with chemical modification;
Slow analysis;
Harsh ionization; Limited
number of molecules can
be analyzed
Poor sensitivity and dynamic
range
Some chemical classes
are not detected
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dynamic range is limited, as when too many ions are in the
trap, space charge effects diminish the performance of the
ion-trap analyzer [29].
The linear time-of-flight (TOF) is the simplest mass
analyzer with a virtually unlimited mass range. It has gained
wide use due to its fast scanning capabilities (milliseconds),
good mass range (up to m/z ~10,000), and an accuracy in the
order of 5 ppm. Quadrupole-TOF mass analyzers combine the
stability of a quadrupole analyzer with high efficiency,
sensitivity, and accuracy of time-of-flight reflectron mass
analyzer and are typically coupled to ESI sources. The
quadrupole can act as a simple quadrupole analyzer to scan
across a specified m/z range. Quadrupole-TOF exploits the
quadrupole’s ability to select a particular ion and the ability of
TOF-MS to achieve simultaneous and accuratemeasurements
of ions across the full mass range. They offer significantly
higher sensitivity and accuracy of tandem quadrupole in-
struments when acquiring full-fragment mass spectra.
FTMS offers high resolution, the ability to performmultiple
collision experiments (MSn), and high-accuracy fragment
masses (often at the part-per-million level). It is now
becoming more common to couple ultra high resolution
(> 105) FTMS to a wide variety of ionization sources, including
MALDI, ESI, APCI and EI (electron impact ionization). Quadru-
pole-FTMS and quadrupole linear ion-trap FTMS mass ana-
lyzers that have recently been introduced are typically
coupled to ESI sources. The quadrupole FTMS combines the
stability of a quadrupole analyzer with high accuracy of FTMS.
A specified m/z range can be scanned by using the quadru-
pole, which can also be used to selectively isolate a precursor
ion. This ion can be directed into the collision cell or the FTMS,
and the resultant precursor and fragment ions can then be
analyzed by the FTMS [29].
MS instrumentation information outlined above will be
important to understand some conclusions in the next MS
biological studies; and hence we hope our review of capacities
of these instruments allows the reader clearer insightsconcerning the biological findings involving MS that we
review below.
2.1. MS studies on estradiol metabolites as potential
cancer biomarkers
Metabolism of estrogens is characterized by two major
pathways, respectively started by hydroxylation in ring A of
molecule (Fig. 1) to produce the 2- and 4-catechol estrogens,
and hydroxylation at the 16α position (Fig. 1). In the catechol
pathway, the metabolism involves further oxidation to
semiquinones and quinones, including formation of the
catechol estrogen-3,4-quinones (E-3,4-Q), the major carcino-
genic metabolites of estrogens. These electrophilic com-
pounds react with DNA to form the depurinating adducts 4-
hydroxyestrone(estradiol)-1-N3Adenine (4-OHE1(E2)-1-N3Ade)
and 4-hydroxyestrone- (estradiol)-1-N7Guanine (4-OHE1(E2)-
1-N7Gua) [1]. Oxidation of catechol estrogens to their qui-
nones is homeostatically controlled which minimizes forma-
tion of the quinones and their apurinic adducts. When the
homeostasis is disrupted, excessive amounts of catechol
estrogen quinones are formed and the resulting increase in
depurinating DNA adducts can lead to initiation of carcino-
genesis [37].
Cavalieri and co-workers conducted several studies using
ESI–MS and LC–MS/MS techniques to prove the formation of
the aforementioned DNA adducts and their relevance in the
initiation of carcinogenesis. Moreover, they used those
techniques to study the effect of specific antioxidants, such
as N-acetylcysteine and resveratrol (Resv), as well as of
different enzymes, on estrogen metabolism [38].
Gaikwad and colleagues studied the evidence for reduction
of the carcinogenic ortho-quinones mediated by NRH quinone
oxidoreductase 2 (NQO2). These authors showed for the first
time that NQO2 catalyzes the reduction of electrophilic
estrogen quinones and thereby may act as a detoxification
enzyme. Binding of E2-3,4-Qwith NQO2was confirmed by ESI–
MS, and further corroborated by analyzing the NQO2-E2-3,4-Q
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Fig. 1 – Biosynthesis andmetabolic activation of estrogens E1 and E2. One of themajor pathways of E1 and E2 leads to 2- and 4-catechol derivatives, which are further oxidized to
yield the corresponding reactive quinones; these can react with DNA to form depurinating DNA adducts. In the deactivation pathway, which operates in parallel, the catechol
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(adapted from [38]) with permissions of authors. 2-OHE1(E2)— 2-hydroxyestrone(estradiol); 4-OHE1(E2)— 4-hydroxyestrone(estradiol); 2-OCH3E1(E2)— 2-methoxyestrone(es-
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spectrometry with a TOF analyzer (MALDI-TOF). Both UV and
LC–MS/MS assays unequivocally corroborate the reduction of
estrogen ortho-quinones by NQO2, indicating that this could
be a novel target for prevention of breast cancer initiation [39].
In a separate report, Gaikwad et al. analyzed urine
samples from 46 healthy control women, 17 women with
breast cancer and 12 women in high risk of acquiring breast
cancer. After partial purification of urine samples by solid
phase extraction (SPE), 40 estrogen-related compounds were
identified and quantitated by ultra-performance liquid chro-
matography–tandemmass spectrometry (UPLC–MS/MS). Each
metabolite was detected and identified based on unique
parameters including mass retention time and ionization
mode (positive or negative). The authors proposed that levels
of depurinating DNA adducts to their respective estrogen
metabolites and conjugates could provide an invaluable
biomarker allowing differentiation between women at high
risk of developing breast cancer, women with breast cancer
and healthy women [40].
The potential function of various cytochrome CYP450
enzymes in oxidizing catechol estrogens to quinones was
identified by Zhang et al. These investigators used different
human CYP isoforms with the aim of oxidizing the catechol
estrogens 2-OHE2 and 4-OHE2 to their respective estrogen
quinones, which then react with DNA to form depurinating
adducts in vitro. The reaction products were analyzed by
UPLC–MS/MS. These experiments demonstrated that CYP
isoforms are able to oxidize catechol estrogens to their
respective quinones, which can further react with proteins,
GSH and DNA, the latter resulting in depurinating adducts
that can lead to mutagenesis [41].
Pruthi et al. conducted a study to determine whether the
ratio of estrogen DNA adducts to their metabolites and
conjugates in serum differed between women with early-
onset breast cancer and those with average or high risk of
developing breast cancer (serum samples from women at
average risk (n = 63) or high risk (n = 80) using Gail model).
The goal of this study was to investigate the imbalance of
estrogen metabolism in serum expressed as estrogen-DNA
adduct ratio to examine its potential as a biomarker for
increased breast cancer risk [42]. Serum samples fromwomen
diagnosed with early breast cancer were analyzed by UPLC–
MS/MS, allowing observation that levels of depurinating
estrogen-DNA adducts were significantly higher in women
at high risk for developing breast cancer than in women at
average risk. These findings suggest that serum estrogen-DNA
adducts are potential biomarkers not only for determining the
risk for developing breast cancer, but also for monitoring the
effects of therapy. Yet, these findings are quite recent and
require further studies towards unequivocal validation [42].
Zahid et al. reported a further study of benzene catechol
(1,2-dihydroxybenzene, CAT) and N-acetyldopamine (NADA),
which is itself a catechol. Benzene is metabolized to phenol in
the liver by cytochrome CYP2E1. Other metabolites include
CAT and hydroxyquinone (1,4-dihydroxybenzene). Oxidation
of CAT and hydroxyquinone is catalyzed by peroxidases,
forming quinones that can exert myelotoxic effects, and
produce stable and depurinating DNA adducts. In this study,
those authors analyzed reactions of catechol quinones suchas the leukemogenic benzene quinone (CAT-Q) and N-
acetyldopamine quinone (NADA-Q) with dG or DNA, using
ESI–MS and UPLC–MS. They concluded that catechol qui-
nones of natural and synthetic estrogens, benzene, naphtha-
lene and dopamine react with DNA through an 1,4-Michael
addition to form predominantly depurinating N3Ade and
N7Gua adducts. With all of these compounds, the N3Ade
adduct depurinates instantaneously from DNA, whereas the
N7Gua adduct depurinates slowly, with a half-time of a few
hours. For that reason, Zahid et al. proposed that common
features may lead to the initiation of cancer and neurode-
generative diseases [43].
The effects of N-acetylcysteine N-AcCys on the metabo-
lism of two cell lines MCF-10F (a normal human breast
epithelial cell line) and E6 (a normal mouse breast epithelial
cell line) were studied by Zahid et al. [43]. The cells were
treated with 4-OHE2 or E2-3,4-Q, after which analysis using
HPLC–EDC (electro-chemical detection) and UPLC–MS/MS
demonstrated that N-AcCys inhibits the formation of depur-
inating adducts in an apparently similar way for both cell
lines, despite originating from different mammal species.
Therefore, it seems that, by blocking formation of estrogen-
DNA adducts, N-AcCys could prevent the initiation of cancer
by estrogens [44].
The same authors conducted another study using MCF-10F
cells to evaluate the prevention of estrogen-DNA adduct
formation by resveratrol (Resv), as Resv acts as both an
antioxidant and an inducer of the phase II enzyme NQO1. The
effects of Resv on the metabolism of estrogens were assessed
by treatment of MCF-10F cells with 4-OHE2 or E2-3,4-Q, where
UPLC–MS/MS was employed to analyze the estrogen-DNA
adducts formed and determine the activity of NQO1 and
catechol-O-methyl transferase (COMT). It was found that Resv
decreased the formation of depurinating estrogen-DNA ad-
ducts from 4-OHE2 or E2-3,4-Q and increased formation of
methoxycatechol estrogens; DNA adducts were not detect-
able, which indicates that Resv may be effective in preventing
estrogen-mediated carcinogenesis by estrogen by blocking
multiple sites in the estrogen genotoxicity pathway, as shown
in Fig. 2 [45].
Gaikwad and colleagues demonstrated the possibility of
circumventing the problem of nonenzymatic reduction of
estrogen quinone by NAD(P)H, given that NQO1 catalyzes the
reduction of estrogen quinones. They performed mass
spectrometric binding studies involving E2-3,4-Q or menadi-
one with NQO1 which support the hypothesis of formation of
an enzyme–substrate complex. Two different strategies were
employed to ascertain the NQO1 activity in estrogen quinone
reduction: first, the ping–pong mechanism of NQO1 catalysis
was utilized to overcome the problem of nonenzymatic
reduction of the substrate by NAD(P)H; second, tetrahydro-
philic acid, which has a reducing potential lower than NAD(P)
H was used as an alternative cofactor. Both strategies
confirmed the reduction of E2-3,4-Q by NQO1, according to
UV or LC/MS–MS analysis of the assaymixtures [10]. In view of
this, the authors concluded that E2-3,4-Q is a substrate for
NQO1, and NQO1 has a significant role in deactivation of
estrogen ortho-quinone that might lead to initiation of cancer
after formation of depurinating DNA adducts. These conclu-
sions have broad implications for development of potential
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initiated carcinogenesis [46].
In another study by Zahid et al., natural antioxidants, such as
N-AcCys, melatonin, reduced lipoic acid and Resv, were investi-
gated for their ability toprevent the reactionof E2-3,4-QwithDNA
[43]. DNA was incubated with E2-3,4-Q or lactoperoxidase-
activated 4-OHE2 in the presence of the antioxidants. After
precipitation of DNA and centrifugation, supernatants were
analyzedbyLC–MS/MSand itwas found thatResvandmelatonin
didnot affect the formationofdepurinatingadductswhenE2-3,4-
Q was reacted with DNA [11]. On the other hand, N-AcCys and
lipoic acid showed a significant inhibition of the formation of
depurinating adducts by E2-3.4-Q. In the case of lactoperoxidase-
activated 4-OHE2 reaction with DNA, Resv achieved the highest
level of inhibition, N-AcCys and reduced lipoic acid produced
moderate inhibition, whereasmelatonin had the least inhibitory
capability. Therefore, this LC–MS/MS study provided demonstra-
tion that all four antioxidants inhibited formation of adducts
involved in malignant transformation of mammary epithelial
cells, identifying them as potential chemo-preventing agents of
cancer initiation, particularly breast and prostate cancer [47].
Gaikwad et al. also reported a study where the aim was to
investigate urine biomarkers of risk in themolecular etiology ofbreast cancer. To this end, urine samples from 40 healthy
control women, 40 high risk women (Gail Model scores were
1.67%–11.7%) and 40 women newly diagnosed with breast
cancer were analyzed by UPLC–MS/MS for quantitation of
estrogen metabolites such as conjugates and depurinating
DNA adducts [38]. At the outset, they confirmed that relatively
high levels of depurinating estrogen-DNA adductswere present
in women at high risk for breast cancer or diagnosed as already
diseased. Estrogen metabolism was shifted from protective
methoxylation and conjugation pathways in the healthy in-
dividuals towards activating pathways leading to formation of
depurinating DNA adducts inwomen at high risk or with breast
cancer. These results support the hypothesis that breast cancer
is initiatedbymutationsderived fromdepurinationof estrogen-
DNA adducts. Therefore, relative levels of depurinating estro-
gen–DNA adducts could become biomarkers for early detection
of breast cancer risk and aid in prevention [38].
A recent analysis of urine samples from premenopausal
womenduring the luteal phaseshowed thatnineof the steroidal
estrogens (E1, E2, 16α-OHE1, E3, 16-ketoE2, 2-OHE1, 2-OHE2, 2-
MeOE1, 4-OHE1) represent more than 90% of the measured
urinary estrogen metabolites [48]. This was corroborated by an
analogous study involving 10 premenopausal women also
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sented 89% of allmeasured urinary estrogenmetabolites [49]. At
a much larger scale, Franke et al. analyzed steroids in 232 urine
samples from 78 premenopausal women, using a benchtop
orbitrap LC–MS and a single quadrupole GC–MS; while GC–MS
allows the measurement of a wide range of steroids, including
non-polar analytes that elude detection by LC–MS, orbitrap-
based LC–MS ismore sensitive, faster, cheaper and allows post-
data acquisition reinterrogation of analytes not targeted a priori
[50]. In this combined LC–MS/GC–MS study, sixteen steroidal
estrogens, includingoxidizedmetabolites, couldbedetected; the
LC–MS/GC–MSSpearman rank correlation coefficients (ρ) for the
relative concentrations of major estrogens E1, E2, E3, 16α-OHE1
and 2-OHE1 were very high (ρ ~ 0.72 to 0.91), and absolute
concentrations as determined by both techniques were also in
agreement (below 5% difference for E1, E2, E3, 16α-OHE1). LC–MS
allowed reinterrogation of the acquired data due to the orbitrap
technology, which permitted post-analysis quantitation of
progesterone, cortisol, and cortisone with an LC–MS/GC–MS ρ
between 0.80 and 0.84, and differences between absolute
concentrations below 7% (n = 13).
Mass spectrometry techniques have also been used in the
survey of potential biomarkers of bladder cancer caused by the
parasitic flatworm Schistosoma haematobium; this eukaryotic
pathogen infectsmillions of peoplemostly in the rural regions
of sub-Saharan Africa, and is associated with high incidence
of bladder cancer, although why this happens remains
uncertain [51]. Since it has long been known that schisto-
somes have estradiol receptors, Botelho et al. conducted a
series of studies on sera from S. haematobium infected persons,
as potentially carcinogenic antigens/components from these
parasites may be useful to decipher schistosome-associated
oncogenesis [52]. These investigators readily identified and
quantitated the sex hormones estradiol, testosterone and
luteinizing stimulating hormone (LH) and found that, in all
cases, serum levels of estradiol were remarkably high as
compared to those in sera from non-infected persons; the
other hormones were not dissimilar from normal levels [52].
In view of this, the authors hypothesized that the levels of
estradiol observed in infected patients were of schistosome
origin, and therefore analyzed the estradiol content in
extracts of worms, finding significant expression of estradi-
ol-relatedmolecules [52,53]. The same investigators employed
LC–ESI–MS to investigate the possible presence of additional
undisclosed estrogenic molecules in worm extracts and sera
of schistosome-infected persons [53,54]; novel estrogen-
related molecules were identified in both worm tissues and
sera of infected individuals, but not in the plasma of a healthy
donor, and their structures suggest that they were formed
upon reaction of estrogen quinone with DNA (Fig. 1). There-
fore, given the aforementioned carcinogenic potential of this
estrogen adduct, the estrogen-related molecules found in
extracts of S. haematobium may be the link between schisto-
somiasis and squamous cell carcinoma of bladder [54].
2.2. MS methods in the analysis of cholesterol, bile acids
and related metabolites
Estrogens have not been the only steroids targeted by MS-
based metabolomics studies: androgens, corticoids and othersteroids such as bile acids, vitamin D, cardiac steroids and
cholesterol itself exhibit physiologically relevant activities,
and therefore are frequently monitored in diverse biological
samples [55]. Due to the metabolic versatility of steroid
molecules, extremely complex mixtures are often encoun-
tered, making their analysis quite demanding and requiring
chromatographic separation prior to MS analysis [52]. Both
GC–MS and LC–MS have been used in the study of steroids and
their metabolites, but LC–MS is considered as the most
promising analytical method for determination of steroids
and steroid conjugates, due to its sensitivity, specificity and
versatility [55,56]. Cholesterol is undeniably the most em-
blematic of all steroids; it is a constituent of cell membranes
and a bioprecursor of bile acids and steroid hormones.
Cholesterol is also one of the major risk factors for arterio-
sclerotic diseases, such as hypertension and cerebrovascular
disease. Thus, the remainder of this review will focus on
informative reports that present MS-based studies on choles-
terol, bile acids and derivatives.
Kock et al. developed an LC-isotope dilution-MS proce-
dure to quantify total cholesterol in serum, without the need
of an in-line derivatization method, using [25,26,27-13C]
cholesterol as the internal standard [56]. A particle-beam
interface was used for coupling the LC and the MS [20],
whereas alkaline hydrolysis followed by extraction with
cyclohexane was employed for sample preparation; results
obtained correlated well with those produced by the stable
isotope dilution GC–MS method, but some interference by
other steroids in the cholesterol quantitation by the LC–MS
approach was observed [55,56].
Griffiths et al. developed prototypic LC–MS/MSmethods for
prenatal diagnosis of Smith–Lemli–Opitz syndrome (SLOS), a
severe disorder in cholesterol synthesis that is classically
diagnosed prenatally by GC–MS analysis of sterol in the
amniotic fluids [57]. The 3β-hydroxysterols from amniotic
fluids were oxidized with cholesterol oxidase to their corre-
sponding 3-ketones, which were then derivatized with Girard
P (GP) hydrazine in a “one-pot” reaction; the GP-hydrazones
formed were analyzed by LC–ESI–MS/MS, and results provided
proof of concept of the potential application of this approach,
once optimized, in the prenatal diagnosis of SLOS [57].
Marbel et al. developed a novel LC–MS/MS method for
quantitative determination of 4β-hydroxycholesterol after
analyte extraction from plasma with hexane and extract
purification by normal-phase SPE followed by 4β-hydroxy-
cholesterol isolation from cholesterol and endogenous iso-
baric plasma oxysterols by reversed-phase HPLC; detection
was achieved by APPI–MS/MS in the positive mode, using
toluene as dopant [58]. This LC–APPI–MS/MS method allowed
quantitation of 4B-hydroxycholesterol in human plasma at
relevant physiological levels (10.0–250 nmol/L), which makes
it highly suited for the clinics, given the method’s high
sensitivity, selectivity, accuracy and relatively short analysis
time [58].
Oxysterols, which are mostly oxygenated forms of choles-
terol in mammals (Fig. 3) recently found to be biologically
active per se [59], have also been the focus of methodological
studies based on MS techniques. For example, Honda and co-
authors [60] described a highly sensitive and specific method,
based on a stable isotope dilution LC–MS/MS technique, for
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one (C4), which has been used as a biomarker for bile acid
biosynthesis [24]. C4 was extracted from human serum by a
salting-out procedure, derivatized into its picolinyl ester and
then isolated by SPE [60] for subsequent quantitation by LC–
ESI–MS/MS; the method provided highly reliable and repro-
ducible results for quantiation of C4 in sera, especially from
small volumes of blood samples [60]. Application of this
method was expanded by these workers for the quantitation,
in serum or rat liver microsomes, of numerous key regulatory
oxysterols [61], and also for the analysis of serum sterol
profiles [62]. These studies provided confirmation that deriv-
atization of (i) dihydroxy- and epoxysterols [61], and (ii)
neutral sterols [62] into the respective picolinyl esters enabled
fast LC–ESI–MS/MS quantitation with high sensitivity and
reproducibility. Also, it allowed to identify, in addition to
cholesterol, 19 cholesterol precursors, cholestanol, campres-
terol, sitosterol, and sitostanol [62]. Overall, this method
seems to be potentially useful in lipid metabolism studies or
in the clinic for (i) diagnosis of cholesterol/oxysterol metab-
olism-related disorders, or (ii) quantitation of serum bio-
markers for the synthesis/absorption of cholesterol.
An alternative method for the quantitation of C4 in serum,
without the need for chemical derivatization, was describedFig. 3 – Biosynthetic pathways for key regulatory oxysterols. Hyd
24S,25-epoxycholesterol is derived from a shunt in the cholester
4β-OH, 4β-hydroxycholesterol; 7α-OH, 7α-hydroxycholesterol;
lesterol; 25-OH, 25-hydroxycholesterol and 27-OH, 27-hydroxychby Lövgren-Sandblom [63]; this method was used successfully
with sera from healthy fasting volunteers, and the findings
obtained were consistent with the possibility that part of 7α-
hydroxy-3-oxo-4-cholestenoic acid in blood originates from
extrahepatic C4. The investigators hypothesized that the rate
of production of C4 in liver is directly reflected by levels of α-
hydroxy-3-oxo-4-cholestenoic acid in blood, which is consis-
tent with use of the latter as a marker for cholesterol 7α-
hydroxylase activity [63].
Oxysterols occur in mammalian brain at ng/g–μg/g levels,
while cholesterol is present at mg/g levels, which makes
oxysterol analysis in brain rather challenging. Karu et al.
developed a nano-LC–MS/MS method for the analysis of
oxysterols in brain, based on SPE of the oxysterol fraction
followed by an oxidation derivatization protocol and then
nano-flow-LC–MSn analysis [64]. According to these authors,
while the oxidation derivatization method improved detec-
tion limits, nano-LC–MSn provided separation of isomers and
allowed for accurate oxysterol quantification [28]; in fact, they
were able to identify 13 discrete oxysterols in rat brain,
including 24S-hydroxycholesterol, 24S-25-epoxycholesterol
and 7α,26-dihydroxycholest-4-en-3-one [64]. The same re-
search group developed a novel LC–MSn methodology for the
identification of cholesterol metabolites in rat brain with highroxycholesterols are synthesized from cholesterol, whereas
ol biosynthetic pathway. CH25H, cholesterol 25-hydroxylase;
22R-OH, 22R-hydroxycholesterol; 24S-OH, 24S-hydroxycho-
olesterol (reproduced from [61].)
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derivatization to enhance ionization, exact mass analysis at
high resolution to identify potential metabolites, and MSn
(n = 3) to allow their structural characterization; this provided
confirmation of 24S-hydroxycholesterol as a major oxysterol
in rat brain, and identification of other formerly undisclosed
oxysterols in brain, such as 24,25-, 24,27-, 25,27-, 6,24-, 7α-25-,
and 7α-27-dihydroxycholesterols. Additionally, two mole-
cules linked to protein amyloidogenesis, 3β-hydroxy-5-oxo-
5,6-seccholestan-6-al and its aldol, were identified in the same
study [65].
An LC–MS/MS approach to determine 24S-hydroxycholes-
terol (24SOHChol) separately from 25-hydroxycholesterol in
plasma was described by DeBarber and colleagues, as blood
levels of 24SOHChol are a practical measure of cholesterol
efflux from human brain; the method was found to be
accurate and free of interference by endogenous 25-hydro-
xycholesterol interference, with the advantage of involving
simplified sample work-up and analysis [66]. Development of
highly sensitive and accurate methods for the analysis of
24SOHChol is extremely relevant also due to the fact that this
oxysterol, as well as 27-hydroxycholesterol, is under investi-
gation as a potential biomarker associated with neurodegen-
erative disorders such as Alzheimer’s disease and multiple
sclerosis [67]. In this context, Griffiths et al. developed a new
LC–MS approach using charge-tagging and high resolution MS
providing identification in plasma of several oxysterols and
downstream metabolites such as, 7α-, 24S-, and 27-hydro-
xycholesterol, the cholestenetriol 7α-27-dihydroxycholes-
terol, and 3β-hydroxycholest-5-en-27-oic acid and its
metabolite 3β-7α-dihydroxycholest-5-en-27-oic acid [67].
The formation of bile acids and bile alcohols is of major
importance for the maintenance of cholesterol homeostasis,
as besides their functions in lipid absorption, bile acids/
alcohols are regulatory molecules for a number of metabolic
processes. Their effects are structure-dependent, and numer-
ous metabolic conversions result in a complex mixture of
biologically active and inactive forms.MS is the basic detection
technique for the analysis of bile acids/alcohols in biological
media, usually after at least an LC separation step. Capillary
LC–ESI–MS normally provides the highest sensitivity, but
depending on the nature of the bile acid/alcohol mixture and
the range of concentrations, discrete sample preparation
sequences, ranging from simple extractions to complex
group separations and derivatizations, are applicable [68].
Ikegawa et al. developed an LC–ESI–MS method for
simultaneous individual determination of different bile acid
3-sulfates in human urine. Urine was subjected to SPE
followed by ion-exchange chromatography on a lipophilic
gel, and then submitted to LC–ESI–MS analysis; the 3-sulfates
were characterized by an abundant pseudo-molecular ion
[M-H]− along with a doubly charged ion [M-2H]2−, whose ratio
was markedly influenced by an acidic component added to
the LC mobile phase [69]. The application of this method to
the analysis of the urine from a healthy volunteer allowed
detection of chenodeoxycholic acid, deoxycholic acid and
lithocholic acid 3-sulfate as glycine conjugates, with very
small amounts of unconjugated and taurine-conjugated bile
acid-3-sulfates [34]. In turn, analysis of urine from patients
with obstructive jaundice led to identification of the glycineconjugates of chenodeoxycholic acid and cholic acid 3-
sulfates, but not of lithocholic acid 3-sulfate [70]. Ikegawa’s
group also developed a method for separation and determi-
nation of bile acid 24-glucuronides in urine using LC–ESI–MS,
to providemore information about themetabolic profile of bile
acids and potentially serve as diagnosis tool for hepatobiliary
diseases. The extracted glucoronides were subjected to LC–
ESI–MS analysis employing an 18O-labeled internal standard,
and detected as intense peaks due to the deprotonated
molecule [M-H]− and a fragment ion [M-H-176]− [69].
LC–ESI–MS studies by Goto et al. provided unprecedented
identification of bile acid acyl galactosides in urine from
healthy donors; urine specimens were subjected to SPE
followed by LC separation and alkalyne hydrolysis, after
which cholic acid (CA) and deoxycholic acid (DCA) were
identified as liberated bile acids, detected along with other
unknown components [71,72]. To identify the latter, a portion
of the alkaline hydrolysate was reacted with 1-phenyl-3-
methyl-5-pyrazolone, which enabled detection of galactose
derivatives by LC–ESI–MS; further analyses, using adequate
controls, provided confirmation of the derivatives structures
as being CA 24-galactoside and DCA 24-galactoside, biosyn-
thesis of which in the human body was thus confirmed.
Goto et al. have also developed a highly sensitive LC/ESI–
MS/MS method, using selected reaction monitoring (SRM)
analysis, for quantitation of bile acid derivatives in human
urine. This provided simultaneous analysis of bile acid 3-
sulfates, including nonamidated glycine-, and taurine-conju-
gated bile acid, cholic acid, chenodeoxycholic acid, deoxy-
cholic acid, ursodeoxycholic acid and lithocholic acid, and
first-time identification of 3β,12α-dihydroxy-5β-cholanoic
acid 3-sulfate in human urine [72].
Last, but not least, Muto et al. recently described a new,
simple and sensitive LC–ESI–MS/MS method for the identifi-
cation and characterization of 39 conjugated and unconju-
gated bile acids, including Δ4-3-oxo- and Δ4,6-3-oxo-bile acids
(markers for Δ4-3-oxo-steroid-5β-reductase deficiency) [73].
In this method, a concentrated desalted urine sample was
diluted in ethanol and directly injected into the LC–ESI–MS/
MS, with detection in the negative ion mode and quantita-
tion by SRM. The remarkable performance of this new
approach was confirmed by comparison with a previously
validated GC–MS analysis method, using urine from patients
with genetically confirmed Δ4-3-oxo-steroid-5β-reductase
deficiency and from a patient with abnormally high levels
of conjugated and unconjugated Δ4-3-oxo-bile acids [73].3. Mass spectrometry to assess
androgen status
The highly sensitive and specific LC–MS/MS methods have
been shown to be superior to conventional immunoassays to
assess low sex hormone concentrations. Haring et al. [74]
determined age-specific reference ranges for LC–MS/MS-
measured total testosterone and prohormone androstenedi-
one (is the most common sex hormone precursor in both
sexes and plays a crucial role in the biosynthesis of
testosterone) as well as calculated free testosterone, in a
large population-based sample of women aged 20–80 years.
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determination of serum sex hormone concentrations in
women and is therefore suitable for routine clinical practice
and research. Thus, the presented age-specific reference
limits are particularly valuable to translate testosterone
concentrations outside the reference range into clinical
treatment and to establish appropriate cutoffs for clinical
guidelines and epidemiological studies [74].
Reference ranges are essential for partitioning testosterone
levels into low or normal and making the diagnosis of
androgen deficiency. Bhasin et al. established reference
ranges for total testosterone and free testosterone in a
community-based sample of men, using liquid chromatogra-
phy tandem mass spectrometry [75]. Reference ranges gener-
ated in a community-based sample of men provide a rational
basis for categorizing testosterone levels as low or normal.
Men with low total testosterone or free testosterone by these
criteria had higher prevalence of physical dysfunction, sexual
dysfunction, and diabetes [75].
The association between aging-related testosterone defi-
ciency and late-onset hypogonadism in men remains a
controversial concept.Mass spectrometrywas used to develop
criteria for identifying late-onset hypogonadism in the general
population on the basis of an association between symptoms
and a low testosterone level [76]. Late-onset hypogonadism
can be defined by the presence of at least three sexual
symptoms associated with a total testosterone level of less
than 11 nmol/L (3.2 ng/mL) and a free testosterone level of less
than 220 pmol/L (64 pg/mL) [76].
Recently, testosterone was measured for the investigation
of femalehyperandrogenismandmalehypogonadism[77]. LC–
MS/MS is becoming the method of choice but comprehensive
reference ranges are lacking. Testosterone was measured by
tandem MS on 90 healthy women, 67 young healthy men and
pregnant women (59 first trimester and 60 second trimester).
The male, male calculated free, first trimester and second
trimester testosterone reference ranges (derived using the
antilog of mean ± 1.96 SD of log transformed data) were 10.6–
31.9, 0.23–0.63, 0.6–4.9 and 0.9–4.9 nmol/L, respectively. The
female testosterone upper reference range limit, derived non-
parametrically from the 97.5th centile, was < 1.7 nmol/L [77].4. Conclusion
The introduction of soft ionization methods in MS and the
evolution of highly sensitive and versatile LC–MS/MS tech-
niques have made possible the analysis of steroid hormones
with small sample requirements, and simplified sample
preparation. The latest reports in this field, as those reviewed
here, demonstrate that MS-based techniques have a central
role in steroidmetabolomics, contributing not only to a deeper
understanding of steroid metabolism, but also to the identi-
fication of clinically relevant disease biomarkers.Acknowledgments
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